View in EDS PDF Full Text

Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction in Patients With Chronic Immune-Mediated Inflammatory Diseases-Reply.

Saved in:
Bibliographic Details
Title: Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction in Patients With Chronic Immune-Mediated Inflammatory Diseases-Reply.
Authors: Syversen SW; Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway., Bolstad N; Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway., Haavardsholm EA; Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway.
Source: JAMA [JAMA] 2021 Sep 21; Vol. 326 (11), pp. 1069-1070.
Publication Type: Letter; Comment
Journal Info: Publisher: American Medical Association Country of Publication: United States NLM ID: 7501160 Publication Model: Print Cited Medium: Internet ISSN: 1538-3598 (Electronic) Linking ISSN: 00987484 NLM ISO Abbreviation: JAMA Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Links:
  – Type: pdflink
Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 34546304
AccessLevel: 2
PubType: Editorial & Opinion
PubTypeId: editorialOpinion
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction in Patients With Chronic Immune-Mediated Inflammatory Diseases-Reply.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Syversen+SW%22">Syversen SW</searchLink>; Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway.<br /><searchLink fieldCode="AU" term="%22Bolstad+N%22">Bolstad N</searchLink>; Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway.<br /><searchLink fieldCode="AU" term="%22Haavardsholm+EA%22">Haavardsholm EA</searchLink>; Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%227501160%22">JAMA</searchLink> [JAMA] 2021 Sep 21; Vol. 326 (11), pp. 1069-1070.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Letter; Comment
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Medical+Association%22">American Medical Association </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>7501160 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1538-3598 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2200987484%22">00987484 </searchLink><i>NLM ISO Abbreviation: </i>JAMA <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=34546304
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1001/jama.2021.11480
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1069
    Titles:
      – TitleFull: Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction in Patients With Chronic Immune-Mediated Inflammatory Diseases-Reply.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Syversen SW
      – PersonEntity:
          Name:
            NameFull: Bolstad N
      – PersonEntity:
          Name:
            NameFull: Haavardsholm EA
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 21
              M: 09
              Text: 2021 Sep 21
              Type: published
              Y: 2021
          Identifiers:
            – Type: issn-electronic
              Value: 1538-3598
          Numbering:
            – Type: volume
              Value: 326
            – Type: issue
              Value: 11
          Titles:
            – TitleFull: JAMA
              Type: main
ResultId 1